Skeletal levels of bisphosphonate in the setting of chronic kidney disease are independent of remodeling rate and lower with fractionated dosing

Chronic kidney disease (CKD) results in a dramatic increase in skeletal fracture risk. Bisphosphates (BP) are an effective treatment for reducing fracture risk but they are not recommended in advanced CKD. We have recently shown higher acute skeletal accumulation of fluorescently-tagged zoledronate...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Bone (New York, N.Y.) N.Y.), 2019-10, Vol.127, p.419-426
Hauptverfasser:	Swallow, Elizabeth A., Aref, Mohammad W., Metzger, Corinne E., Sacks, Spencer, Lehmkuhler, Demi R., Chen, Neal, Hammond, Max A., Territo, Paul R., Nickolas, Thomas L., Moe, Sharon M., Allen, Matthew R.
Format:	Artikel
Sprache:	eng
Schlagworte:	Animal model Bisphosphonate Bone CKD Drug accumulation
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!